

(21) Application No: 0621466.2

(22) Date of Filing: 31.03.2005

(30) Priority Data:
(31) 2004108570 (32) 31.03.2004 (33) JP

(86) International Application Data:
PCT/JP2005/006364 Jp 31.03.2005

(87) International Publication Data:
WO2005/095600 Jp 13.10.2005

(71) Applicant(s):
National Institute of Advanced Industrial Science and
Technology
(Incorporated in Japan)
3-1, Kasumigaseki 1-chome, Chiyoda-ku,
Tokyo 1008921, Japan

(continued on next page)

(51) INT CL:
C07K 14/50 (2006.01) A61K 38/00 (2006.01)
C12N 15/09 (2006.01) C12P 21/02 (2006.01)


(52) UK CL (Edition X):
C3H HB7M H672 H690
U1S S4001 S4020

(56) Documents Cited by ISA:
JP 110137255 A
Seikagaku (Aug 2004); Vol 76, p 1006, "Modification of
FGF-1,...", Asada et al
Trends in Glycoscience & Glycotechnology (2001); Vol
13, pp 385-394, "Engineering of a heparin-binding...",
Asada et al
Cell Technology (2000); Vol 19, pp 1338-1340,
"Syndecan tono yugo...", Yoneda et al
Seikagaku (2002); Vol 74, p 848, "Tosa donyu ni
yoru...", Asada et al
Nature Biotechnology (2000), Vol 18, pp 641-644,
"Engineering with an FGF-proteoglycan...", Yoneda et
al

(continued on next page)

(54) Abstract Title: Heparin-Binding Protein Having Heparan Sulfate Sugar Chain Attached Thereto Process For Producing The Same And Medicinal Composition Containing The Same

(57) A cDNA encoding a peptide capable of having selective heparan sulfate-attachment is bonded to another cDNA encoding a heparin-binding protein and the gene product of this bonded cDNA is produced by animal cells, thereby producing a heparin-binding protein having a heparan sulfate sugar chain attached via a covalent bond in its molecule. Because of having a sulfated glycosaminoglycan sugar chain with little chondroitin sulfate covalently bonded thereto, this heparin-binding protein having a heparan sulfate sugar chain attached thereto has high functions such as being stable to, for example, heat, acids, alkalis and so on in vivo, is effective in cell growth, tissue regeneration and so on, and, moreover, has an effect of controlling the physiological function of FGF. Thus, it is highly useful as a drug for preventing and treating various diseases in which FGF participates.



GB 2427863 A continuation

(72) Inventor(s):

**Toru Imamura
Masahiro Asada
Masashi Suzuki**

(74) Agent and/or Address for Service:

**D Young & Co
120 Holborn, LONDON, EC1N 2DY,
United Kingdom**

(58) Field of Search by ISA:

**INT CL A61K, C07K, C12N, C12P
Other: JICST FILE (JOIS), EUROPAT (QUESTEL),
MEDLINE/BIOSIS/WPIDS (STN),
SwissProt/PIR/GeneSeq,
Genbank/EMBL/DDBJ/GeneSeq**